Rx Prescripttion Only-YMYL Medical Content

Ascimib 40 mg

Asciminib 40mg tablets – Everest Pharmaceuticals Ltd.

Approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) — both newly diagnosed patients and those previously treated with two or more tyrosine kinase inhibitors — and specifically for Ph+ CML-CP with the T315I mutation, the resistance mutation that defeats imatinib, dasatinib, nilotinib, and bosutinib.

25.5%

Major molecular response at 24 weeks vs 13.2% with bosutinib (ASCEMBL trial)

37.6%

MMR rate at 96 weeks vs 15.8% with bosutinib — gap widened over time

5.1%

Discontinued due to side effects vs 21.1% with bosutinib — markedly better tolerability

STAMP

First-in-class mechanism — binds a different site than all earlier BCR-ABL inhibitors

Confirm BCR-ABL1 status and treatment history

Requires confirmed Philadelphia chromosome / BCR-ABL1 fusion. Determine whether you are newly diagnosed, have failed two or more prior TKIs, or carry the specific T315I mutation — each maps to a different approved dose.

Review pancreatic enzyme levels and abdominal symptom history

Baseline amylase and lipase testing recommended, with monthly monitoring — asciminib can cause pancreatitis, sometimes without other warning signs.

Assess cardiovascular risk and current medications

Cardiovascular events (heart attack, stroke, blood clots), hypertension, and QT prolongation have occurred — baseline blood pressure and cardiac history review needed. Asciminib is a CYP3A4 substrate, so strong CYP3A4 inhibitors significantly increase drug exposure.

Discuss goals of care, especially after multiple prior TKI failures

For heavily pretreated patients, weigh asciminib’s notably better tolerability (lower discontinuation due to side effects) against modest but real molecular response rates — particularly relevant when quality of life on prior TKIs has been difficult.

Important safety information: Asciminib can cause pancreatitis — sometimes detected only through elevated amylase/lipase before symptoms appear — myelosuppression (low blood counts), hypertension, and cardiovascular events including heart attack, stroke, and blood clots. QT interval prolongation has also been reported. Asciminib can cause embryo-fetal harm; effective contraception is required during treatment and for at least one week after the final dose. Do not breastfeed during treatment.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Asciminib’s STAMP mechanism is genuinely novel — it binds a completely different site on BCR-ABL than every prior TKI, which is why it can work even against many resistance mutations. What stood out most in ASCEMBL wasn’t just the efficacy advantage over bosutinib, but how much better tolerated it was — far fewer patients stopped due to side effects. For patients who’ve struggled through multiple prior TKIs, that tolerability difference matters as much as the molecular response data.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my hematologist about starting asciminib?

Here are key questions to bring to your hematologist — given asciminib’s distinctive mechanism and the significant dose difference depending on your specific situation, confirming exactly which regimen applies to you is the natural starting point.

Before confirming asciminib as your treatment

Has my BCR-ABL1 status been confirmed, and what is my specific situation — newly diagnosed CML, prior treatment with two or more TKIs, or confirmed T315I mutation?
Which dose applies to me — 80mg once daily, 40mg twice daily, or 200mg twice daily for T315I — and why that specific regimen?
What prior TKIs have I tried, and how did I respond or tolerate them?
Why is asciminib being recommended at this point rather than another TKI?

About the pancreatitis risk — a distinctive monitoring requirement

Will my amylase and lipase levels be checked at baseline, and how often afterward — monthly, or as needed?
What symptoms of pancreatitis — severe upper abdominal pain radiating to the back, nausea, vomiting — should prompt me to stop the medication and seek care immediately?
If my pancreatic enzymes come back elevated without symptoms, what happens — dose adjustment, temporary pause, or just closer monitoring?
Do I have any history of pancreatitis, gallstones, or heavy alcohol use that changes this risk?

About cardiovascular monitoring

Will my blood pressure be checked regularly, and what reading would require treatment or dose adjustment?
Do I need a baseline ECG given the QT prolongation risk?
What symptoms of a cardiovascular event — chest pain, sudden weakness on one side, slurred speech, leg swelling or pain — require emergency care?
Do I have any cardiovascular risk factors (smoking, diabetes, high cholesterol, prior heart issues) that change how closely this needs to be watched?

About blood count monitoring

How often will my complete blood count be checked, especially given the thrombocytopenia risk seen in trials?
What platelet or neutrophil levels would trigger a dose change?
What symptoms — unusual bruising or bleeding, signs of infection, profound fatigue — should prompt an urgent call?

About drug interactions

Am I currently taking any medications that are strong CYP3A4 inhibitors — certain antifungals, some antibiotics, certain HIV medications, or grapefruit products — since these significantly increase asciminib exposure?
If I need a new medication from another doctor, what should they know about this interaction?

About dosing and administration

Should I take this at the same time each day, and does food matter?
What happens if I miss a dose?
For the twice-daily regimen specifically, how many hours apart should the two doses be?

About monitoring response

How will we track whether this is working — specifically, what BCR-ABL percentage milestones are we aiming for, and on what timeline?
How often will PCR monitoring be done?
At what point would we know asciminib isn’t working well enough, and what would that conversation look like?

About my specific situation

If I’m of childbearing potential, what contraception is required during treatment, and for how long after stopping?
Should I avoid breastfeeding, and for how long after my last dose?
Does my liver or kidney function affect my dose, given that no adjustment is typically needed for renal or hepatic impairment — does that apply to my specific situation?

About the longer road

If asciminib doesn’t achieve an adequate response, what would be considered next?
Given how new this drug is in the first-line setting, is there anything specific being monitored or studied about its long-term use that I should know about?
Are there patient assistance programs through Novartis if cost is a concern?

A practical tip: Because pancreatitis can sometimes show up first as an asymptomatic lab abnormality before any physical symptoms develop, it’s worth specifically confirming the monitoring schedule for amylase and lipase in writing, along with what specific result would prompt a call versus a scheduled follow-up — this is one of the less intuitive monitoring requirements compared to more familiar things like blood counts or blood pressure.

compare with other therapies

Compare asciminib vs ponatinib for T315I-mutated CML

This is one of the most evidence-rich and actively debated comparisons in current CML treatment — and unlike most comparisons we’ve covered, this one involves genuinely conflicting findings depending on which study you look at, which is worth being transparent about.

Both are approved specifically for T315I — a small, exclusive category

Ponatinib and asciminib are the only two drugs approved in the United States for patients with the T315I mutation. In Europe, only ponatinib is approved for this mutation. This regulatory difference between the US and Europe is itself worth knowing if you’re navigating treatment outside the US.

Mechanism — fundamentally different approaches to the same target

	Ponatinib (Iclusig)	Asciminib (Scemblix)
Binding site	ATP-competitive (active site)	Allosteric — specifically targets the ABL myristoyl pocket (STAMP), locking BCR::ABL1 in an inactive conformation
T315I dose	45mg, 30mg, or 15mg once daily (OPTIC trial doses)	200mg twice daily — a notably higher dose than asciminib’s standard regimen, since 4- to 13-fold higher concentration is needed to inhibit the T315I-mutated form

Efficacy — the picture is genuinely contested

This is where I want to be careful not to oversimplify, because different analyses point in different directions:

In the asciminib phase 1 trial with up to 6 years’ follow-up, durable MMR was achieved in 53% of patients with T315I-mutated disease, and a separate 2-year follow-up analysis (X2101) supported an MMR rate of 49% by 96 weeks.

In ponatinib’s OPTIC trial, 51.6% of patients on the 45mg starting dose achieved BCR::ABL1 ≤1% by 12 months — a different endpoint than MMR, making direct comparison tricky.

A more rigorous attempt to compare them directly — a matching-adjusted indirect comparison (MAIC) using individual patient-level data — found that in patients with the T315I mutation specifically, ponatinib showed a statistically significant advantage over asciminib: a 43.54% higher rate of achieving BCR::ABL1 ≤1%, and a 47.37% higher MMR rate by 12 months.

An independent commentary specifically flagged that this remains a cross-trial comparison limitation: given MMR rates of 24% to 45% in the PACE and OPTIC ponatinib trials, it remains unclear whether asciminib would actually out-perform ponatinib in a true head-to-head trial — which doesn’t yet exist.

The honest summary: the best available adjusted analysis currently favors ponatinib for raw efficacy in T315I-mutated disease specifically, but this is based on indirect statistical matching rather than a direct randomized comparison, and real-world retrospective data is still being gathered to clarify this.

Safety — this is where asciminib’s advantage is more consistent

Ponatinib’s cardiovascular risk includes arterial occlusive events in 14% to 31% of patients with CML-CP, though rates can be reduced by approximately 60% using response-based dose-reduction strategies.

In the long-term asciminib T315I follow-up, 2 of the patients with baseline cardiovascular risk factors experienced arterial occlusive events (12.5%) — one with acute coronary syndrome who continued asciminib, and one with a fatal stroke and heart attack after discontinuation. A separate analysis found the frequency of arterial occlusive events was 5.1% with asciminib compared to 1.3% with bosutinib — meaning asciminib’s cardiovascular signal, while lower than ponatinib’s, is not zero.

A clinical discussion among CML specialists summarized this trade-off clearly: ponatinib generally carries more cardiovascular concerns but offers broader mutation coverage, while asciminib offers more favorable tolerability but more specific targeting of BCR::ABL1.

Real-world retrospective data — a useful third data point

A retrospective study comparing 99 patients with T315I-mutated CML across 9 countries found that resistance was the primary cause of treatment failure in 59% of the asciminib group versus 90% of the ponatinib group — though this study also noted the asciminib group was notably older (median age 62 vs 50) than the ponatinib group, an important confounding factor that makes interpretation difficult without further adjustment.

Prior ponatinib treatment doesn’t rule out asciminib

Asciminib remains an effective treatment option for patients with T315I-mutated CML-CP, including those who had prior ponatinib treatment — meaning sequencing from one to the other (rather than choosing permanently between them) is a clinically supported strategy when needed.

How the choice tends to play out in practice

Favor ponatinib when:

No significant cardiovascular risk factors are present
Maximizing molecular response depth is the immediate priority
Response-based dose reduction strategies can be actively managed to mitigate cardiovascular risk

Favor asciminib when:

Significant cardiovascular risk factors are present (prior heart attack, stroke, peripheral artery disease, uncontrolled hypertension)
The patient has already tried and not tolerated ponatinib
Tolerability and quality of life are the dominant concern, particularly in older or frailer patients
Pancreatic history makes the more established pancreatitis monitoring protocol of asciminib relevant to discuss instead of a different toxicity profile

Bottom line

This is one of the genuinely unresolved questions in current CML care — the best available indirect evidence suggests ponatinib may have an efficacy edge in T315I-mutated disease specifically, while asciminib offers a more favorable (though not risk-free) cardiovascular and overall tolerability profile. No head-to-head randomized trial exists yet to settle this definitively, so the decision in your specific case will depend heavily on your cardiovascular risk profile, how you’ve tolerated prior TKIs, and your hematologist’s read of the evolving real-world and retrospective data. This is exactly the kind of nuanced, evidence-still-emerging decision worth discussing in depth with a CML specialist, ideally one who manages T315I-mutated cases regularly given how rare and specialized this scenario is.

How does testing work

What does the STAMP mechanism mean and how is asciminib different from other BCR-ABL inhibitors?

STAMP stands for Specifically Targeting the ABL Myristoyl Pocket — and understanding it requires stepping back to look at how every other BCR-ABL inhibitor in our CML series (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) actually works, because asciminib does something genuinely different at the molecular level.

How traditional TKIs work — the ATP-binding site

BCR-ABL1 is a kinase — an enzyme that adds phosphate groups to other proteins using ATP as the phosphate source. This phosphate-transfer activity happens at a specific location on the protein called the ATP-binding site (or active site).

Imatinib, dasatinib, nilotinib, bosutinib, and ponatinib are all ATP-competitive inhibitors — they work by physically occupying the ATP-binding site, blocking ATP from getting in and preventing the kinase from doing its job. Think of it like jamming a key into a lock so the real key can’t be inserted.

This approach has a structural vulnerability: the ATP-binding site is also the location where most resistance mutations occur, including T315I. The “I” in T315I refers to isoleucine replacing threonine at a specific position right at this binding site — and that substitution creates a steric (physical space) obstruction that prevents most ATP-competitive drugs from fitting properly, the molecular equivalent of changing the shape of the lock so the jammed key no longer fits.

How asciminib works — a completely different binding location

Asciminib works by specifically targeting the ABL myristoyl pocket, inhibiting BCR::ABL1 kinase activity by locking it in an inactive conformation via allosteric binding.

The myristoyl pocket is a separate site on the ABL protein, located away from the ATP-binding site entirely. In normal, healthy ABL protein (before the BCR-ABL fusion forms), a fatty molecule called myristate naturally sits in this pocket and helps keep the protein folded into an inactive, “off” shape — a built-in safety switch. When the Philadelphia chromosome creates the BCR-ABL fusion protein, part of this natural self-regulation is disrupted, contributing to the protein being stuck in an “always on” growth-signaling state.

Asciminib essentially restores this natural inactive switch by occupying that same myristoyl pocket, allosterically forcing the kinase back into its closed, inactive conformation — shutting down its activity from a completely different angle than every other approved TKI.

Why this matters for resistance mutations

Because T315I and most other kinase-domain resistance mutations occur at or near the ATP-binding site, they don’t interfere with asciminib’s binding location at all — the myristoyl pocket is structurally untouched by these mutations. This is why asciminib remains effective against BCR::ABL1 kinase domain mutations, including T315I — it’s not that asciminib is simply “stronger,” it’s that it’s attacking from a location the mutation never evolved to defend.

That said, T315I does still reduce asciminib’s potency somewhat — preclinical data showed 4- to 13-fold higher asciminib concentration is needed to adequately inhibit T315I-mutated BCR::ABL1 compared to non-mutated BCR::ABL1, which is precisely why the T315I-specific dose (200mg twice daily) is so much higher than the standard dose (80mg once daily or 40mg twice daily) — the drug still works, but needs a higher concentration to overcome the mutation’s partial interference even from a different binding site.

Why “allosteric” matters as a concept

“Allosteric” describes any mechanism where a molecule binds somewhere other than a protein’s main active site but still changes that protein’s shape or function — essentially influencing behavior through structural change rather than direct blockade. This is a meaningfully different drug design philosophy from the ATP-competitive approach, and asciminib represents the first approved BCR::ABL1 inhibitor to work this way.

The practical clinical consequence — off-target effects

ATP-binding sites are structurally similar across many different kinases in the body, which is part of why ATP-competitive TKIs often have broader “off-target” activity — hitting other kinases like PDGFR, KIT, or VEGFR (as we saw with sorafenib and pazopanib) in addition to BCR-ABL. This off-target activity contributes to many of the side effects associated with those drugs.

The myristoyl pocket asciminib targets is far more structurally unique to ABL kinases specifically, which is part of why asciminib tends to have a narrower side-effect profile focused more specifically on BCR-ABL-related effects, with less of the broad multi-kinase toxicity pattern seen with drugs like ponatinib, sorafenib, or pazopanib.

A nuance worth understanding: this doesn’t mean zero off-target risk

It’s worth being precise here — asciminib isn’t free of cardiovascular signal entirely. The frequency of arterial occlusive events was found to be 5.1% with asciminib compared to 1.3% with bosutinib in longer-term ASCEMBL follow-up, so the more targeted mechanism doesn’t fully eliminate cardiovascular risk — it appears meaningfully reduced compared to ponatinib, but not absent.

Why this represents a genuine innovation, not just marketing language

The STAMP mechanism isn’t simply a more refined version of existing TKI chemistry — it’s a structurally distinct approach to inhibiting the same disease-driving protein. This is conceptually similar to how, in a lock-and-key analogy, instead of making increasingly specialized keys for an increasingly modified lock (the approach with imatinib → dasatinib/nilotinib → ponatinib, each generation handling more resistance mutations at the same general binding location), asciminib instead found an entirely different door into the same building.

This is also why ongoing combination research is exploring whether asciminib plus an ATP-competitive TKI together might work even better than either alone — since they bind different locations, simultaneously occupying both the ATP site and the myristoyl pocket could, in theory, make it much harder for the cancer to develop resistance through either single mutation pathway alone.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.